Modified response evaluation criteria in solid tumors and european association for the study of the liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization

Journal of Vascular and Interventional Radiology

Volumn 25, Issue 2, 2014, Pages 256-265

  Camacho, Juan C ^a   Kokabi, Nima ^a   Xing, Minzhi ^a   Prajapati, Hasmukh J ^a   El Rayes, Bassel ^b   Kim, Hyun S ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MICROSPHERE; OXALIPLATIN; PACLITAXEL; YTTRIUM 90;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTED TOMOGRAPHY SCANNER; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DISEASE CLASSIFICATION; EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER; FEMALE; HUMAN; INOPERABLE CANCER; INSTITUTIONAL REVIEW; INTERVENTIONAL RADIOLOGY; KAPLAN MEIER METHOD; LOG RANK TEST; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SCANNER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOEMBOLIZATION; RESPONSE CRITERIA IN SOLID TUMORS; SCORING SYSTEM; SOLID TUMOR; STANDARD; TREATMENT RESPONSE; VERY ELDERLY; YOUNG ADULT;

COMPLETE RESPONSE; CR; EASL; EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER; ICC; INTRAHEPATIC CHOLANGIOCARCINOMA; MODIFIED RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; MRECIST; PARTIAL RESPONSE; PD; PR; PROGRESSIVE DISEASE; RECIST; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;

ADULT; AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; EMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIDETECTOR COMPUTED TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN; YTTRIUM RADIOISOTOPES;

EID: 84893070916     PISSN: 10510443     EISSN: 15357732     Source Type: Journal    
DOI: 10.1016/j.jvir.2013.10.056     Document Type: Article

References (37)

1. T. Patel, and P. Singh Cholangiocarcinoma: emerging approaches to a challenging cancer Curr Opin Gastroenterol 23 2007 317 323
2. S.A. Khan, H.C. Thomas, B.R. Davidson, and S.D. Taylor-Robinson Cholangiocarcinoma Lancet 366 2005 1303 1314
3. Y.E. Chung, M.J. Kim, and Y.N. Park et al. Varying appearances of cholangiocarcinoma: radiologic-pathologic correlation Radiographics 29 2009 683 700
4. K.N. Lazaridis, and G.J. Gores Cholangiocarcinoma Gastroenterology 128 2005 1655 1667
5. D.C. Doval, J.S. Sekhon, and S.K. Gupta et al. A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer Br J Cancer 90 2004 1516 1520
6. T. Andre, C. Tournigand, and O. Rosmorduc et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study Ann Oncol 15 2004 1339 1343
7. S.R. Alberts, H. Al-Khatib, and M.R. Mahoney et al. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial Cancer 103 2005 111 118
8. J. Valle, H. Wasan, and D.H. Palmer et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer N Engl J Med 362 2010 1273 1281
9. R.T. Hoffmann, P.M. Paprottka, and A. Schon et al. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival Cardiovasc Intervent Radiol 35 2012 105 116
10. S. Mouli, K. Memon, and T. Baker et al. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis J Vasc Interv Radiol 24 2013 1227 1234
11. S. Rafi, S.M. Piduru, and B. El-Rayes et al. Yttrium-90 Radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study Cardiovasc Intervent Radiol 36 2013 440 448
12. A. Saxena, L. Bester, T.C. Chua, F.C. Chu, and D.L. Morris Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option Ann Surg Oncol 17 2010 484 491
13. S.M. Ibrahim, M.F. Mulcahy, and R.J. Lewandowski et al. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study Cancer 113 2008 2119 2128
14. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
15. A.B. Miller, B. Hoogstraten, M. Staquet, and A. Winkler Reporting results of cancer treatment Cancer 47 1981 207 214
16. J. Bruix, M. Sherman, and J.M. Llovet et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver J Hepatol 35 2001 421 430
17. A. Forner, C. Ayuso, and M. Varela et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 115 2009 616 623
18. R.L. Wahl, H. Jacene, Y. Kasamon, and M.A. Lodge From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors J Nucl Med 50 suppl 1 2009 122S 150S
19. R. Lencioni, and J.M. Llovet Modified RECIST (mRECIST) assessment for hepatocellular carcinoma Semin Liver Dis 30 2010 52 60
20. M. Schmeding, and U.P. Neumann Liver transplantation for intra- and extrahepatic cholangiocarcinoma Ann Transplant 18 2013 1 8
21. R. Salem, P. Parikh, and B. Atassi et al. Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution Am J Clin Oncol 31 2008 431 438
22. L. Bester, and R. Salem Reduction of arteriohepatovenous shunting by temporary balloon occlusion in patients undergoing radioembolization J Vasc Interv Radiol 18 2007 1310 1314
23. R.J. Lewandowski, K.T. Sato, and B. Atassi et al. Radioembolization with 90Y microspheres: angiographic and technical considerations Cardiovasc Intervent Radiol 30 2007 571 592
24. R. Salem, and K.G. Thurston Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerations J Vasc Interv Radiol 17 2006 1251 1278
25. E.A. Eisenhauer, P. Therasse, and J. Bogaerts et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
26. H.J. Prajapati, J.R. Spivey, and S.I. Hanish et al. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE) Ann Oncol 24 2013 965 973
27. J.M. Bland, and D.G. Altman The logrank test Br Med J 328 2004 1073
28. J.R. Anderson, K.C. Cain, and R.D. Gelber Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables J Clin Oncol 26 2008 3913 3915
29. M.F. Chen Peripheral cholangiocarcinoma (cholangiocellular carcinoma): clinical features, diagnosis and treatment J Gastroenterol Hepatol 14 1999 1144 1149
30. M.T. Carriaga, and D.E. Henson Liver, gallbladder, extrahepatic bile ducts, and pancreas Cancer 75 1995 171 190
31. F.D. Gonzalez-Guindalini, M.P. Botelho, and C.B. Harmath et al. Assessment of liver tumor response to therapy: role of quantitative imaging Radiographics 33 2013 1781 1800
32. J.H. Shim, H.C. Lee, and S.O. Kim et al. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models Radiology 262 2012 708 718
33. W.C. Yu, K.Z. Zhang, S.G. Chen, H.L. Lin, and W. Wei Comparison of response evaluation criteria in solid tumors (RECIST), European Association for the study of the liver (EASL) and modified RECIST criteria in evaluation of tumor response after transarterial chemoembolization of primary liver cancer Chin J Radiol 45 2011 766 769
34. R.S. Benjamin, H. Choi, and H.A. Macapinlac et al. We should desist using RECIST, at least in GIST J Clin Oncol 25 2007 1760 1764
35. E.S. Jung, J.H. Kim, and E.L. Yoon et al. Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization J Hepatol 58 2013 1181 1187
36. L. Mannelli, S. Kim, C.H. Hajdu, J.S. Babb, T.W. Clark, and B. Taouli Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver AJR Am J Roentgenol 193 2009 1044 1052
37. R. Dhanasekaran, D.A. Kooby, C.A. Staley, J.S. Kauh, V. Khanna, and H.S. Kim Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study HPB (Oxford) 12 2010 174 180